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Abstract
Background: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel 
selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal 
osteoporosis.
Methods: Healthy postmenopausal osteoporotic women (N = 7,492; mean age, 66.4 years) were randomized to daily 
doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo for 3 years. Safety and tolerability were assessed by 
adverse event (AE) reporting and routine physical, gynecologic, and breast examination.
Results: Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs in the bazedoxifene groups was not 
different from that seen in the placebo group. The incidence of hot flushes and leg cramps was higher with 
bazedoxifene or raloxifene compared with placebo. The rates of cardiac disorders and cerebrovascular events were low 
and evenly distributed among groups. Venous thromboembolic events, primarily deep vein thromboses, were more 
frequently reported in the active treatment groups compared with the placebo group; rates were similar with 
bazedoxifene and raloxifene. Bazedoxifene showed a neutral effect on the breast and an excellent endometrial safety 
profile. The incidence of fibrocystic breast disease was lower with bazedoxifene 20 and 40 mg versus raloxifene or 
placebo. Reductions in total and low-density lipoprotein levels and increases in high-density lipoprotein levels were 
seen with bazedoxifene versus placebo; similar results were seen with raloxifene. Triglyceride levels were similar among 
groups.
Conclusion: Bazedoxifene showed a favorable safety and tolerability profile in women with postmenopausal 
osteoporosis.
Trial Registration: Trial registration number: NCT00205777; Trial registration date: September 16, 2005
Background
Postmenopausal women experiencing declining levels of
endogenous estrogens are disproportionately affected by
osteoporosis, which affects one third of women between
the ages of 60 and 70 years and two thirds of women 80
years and older [1]. Numerous agents for the prevention
and/or treatment of postmenopausal osteoporosis are
currently available, including bisphosphonates, estrogen
therapy, parathyroid hormone (PTH), calcitonin, and the
selective estrogen receptor modulator (SERM) raloxifene
[2]. Although existing pharmacologic agents for post-
menopausal osteoporosis have been shown to be effective
in preventing bone loss and fractures [3], there remains
an ongoing need to provide women with new therapeutic
options, primarily due to variable safety and tolerability
profiles.
SERMs, also referred to as estrogen agonists/antago-
nists, are a structurally diverse group of compounds that
can confer estrogen receptor agonist or antagonist effects
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depending on the target tissue, making them attractive
candidates for the prevention and/or treatment of post-
menopausal osteoporosis [4]. Bazedoxifene is a novel
SERM that was developed using a stringent preclinical
screening process designed to select compounds with
favorable effects on bone and lipid profiles while mini-
mizing stimulation of uterine or breast tissue [4,5]. In a
phase 2 study of healthy postmenopausal women, daily
oral doses of bazedoxifene 2.5, 5.0, 10, 20, 30, or 40 mg
were generally well tolerated and did not stimulate the
endometrium [6]. Moreover, bazedoxifene 30 and 40 mg
showed significantly smaller increases in endometrial
thickness and significantly reduced the incidence of uter-
ine bleeding compared with placebo [6]. In a 2-year phase
3 study of postmenopausal women at risk for osteoporo-
sis, bazedoxifene 10, 20, and 40 mg was shown to prevent
bone loss and reduce bone turnover and was associated
with a favorable endometrial, ovarian, and breast safety
profile [7,8].
A pivotal, global phase 3 study in postmenopausal
women with osteoporosis showed that bazedoxifene 20
and 40 mg and raloxifene 60 mg significantly reduced the
risk of new vertebral fracture relative to placebo over 3
years of therapy [9]. A post hoc analysis of a subgroup of
women at higher risk for fracture showed that bazedox-
ifene 20 mg significantly reduced the risk of nonvertebral
fracture [9]. Here we report the results of the safety evalu-
ations from that study.
Methods
Study design
Full details of the study design and methodology have
been previously reported [9]. This was a 3-year multi-
center, randomized, double-blind, placebo- and active-
controlled phase 3 trial (NCT00205777) conducted at
206 sites worldwide (and continuing as an ongoing study
extension for 4 additional years). Eligible subjects were
generally healthy postmenopausal women aged 55 to 85
years with osteoporosis, defined as low bone mineral
density (BMD) or radiographically confirmed vertebral
fractures. Subjects without prevalent vertebral fracture
were required to have lumbar spine or femoral neck BMD
T-scores between -2.5 and -4.0 (inclusive), whereas sub-
jects with prevalent vertebral fracture (at least 1 mild ver-
tebral fracture) were required to have lumbar spine and
femoral neck BMD T-scores not worse than -4.0.
Table 1: Baseline Characteristics (Safety Population)
Bazedoxifene Raloxifene Placebo
Characteristic 20 mg
(n = 1886)
40 mg
(n = 1872)
60 mg
(n = 1849) (n = 1885)
Age, y
Mean (SD) 66.5 (6.5) 66.2 (6.8) 66.4 (6.7) 66.5 (6.8)
Ethnic origin, n (%)
White 1657 (87.9) 1623 (86.7) 1618 (87.5) 1641 (87.1)
Black 115 (6.1) 135 (7.2) 116 (6.3) 120 (6.4)
Hispanic 90 (4.8) 83 (4.4) 87 (4.7) 88 (4.7)
Othera 24 (1.3) 31 (1.7) 28 (1.5) 36 (1.9)
Years since last menstrual period
Mean (SD) 19.7 (8.6) 19.3 (8.9) 19.5 (8.7) 19.5 (8.8)
Hysterectomy, n (%) 430 (22.8) 403 (21.5) 374 (20.2) 360 (19.1)
Type of menopause, n (%)
Natural 1706 (90.5) 1690 (90.3) 1700 (91.9) 1738 (92.2)
Surgical oophorectomy 180 (9.5) 182 (9.7) 149 (8.1) 147 (7.8)
Subjects reporting hot flushes, n (%)b 287 (15.2) 316 (16.9) 264 (14.3) 251 (13.3)
Hot flushes per day
Mean (SD) 2.2 (2.4) 2.1 (2.2) 1.9 (1.9) 2.0 (2.1)
BMI, kg/m2
Mean (SD) 26.6 (3.8) 26.5 (3.9) 26.4 (3.8) 26.3 (3.8)
SD, standard deviation; BMI, body mass index.
aIncludes Asian, Native American, Pacific Islander, and other ethnic origins.
bP < 0.05; Chi-square test.Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
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Exclusion criteria included diseases that may affect
bone metabolism or conditions that could interfere with
measurement of BMD, pathologic vertebral fractures,
vasomotor symptoms requiring treatment, active or past
history of venous thromboembolic events (VTEs), endo-
metrial hyperplasia or carcinoma, abnormal vaginal
bleeding, or malignancy within 10 years of the study. Sub-
jects were prohibited from the use of any drug known to
have an effect on bone metabolism, including androgens,
systemic estrogens (except estriol ≤2.0 mg/day), topical
estrogens (>3 times/week), progestogens, SERMs, bis-
phosphonates, calcitonin, PTH, and cholecalciferol
(>50,000 IU/week) within 6 months of screening.
Eligible subjects were randomly assigned to receive a
once-daily oral dose of bazedoxifene 20 or 40 mg, ralox-
ifene 60 mg, or placebo for 3 years. All subjects were to
receive daily supplementation with oral calcium (1,000-
1,200 mg) and vitamin D (400-800 IU).
Non-hysterectomized women were eligible for partici-
pation in an endometrial safety substudy designed to
examine measures related to the endometrium and ova-
ries [10]. Subjects with endometrial thickness >5 mm as
measured by transvaginal ultrasound (TVU) or endome-
trial hyperplasia or carcinoma on baseline biopsy were
excluded from the substudy.
The study protocol and an informed consent form were
submitted to the independent ethics committee or insti-
tutional review board at each institution for review and
written approval. All subjects provided written informed
consent prior to enrollment in the study, which was con-
ducted in accordance with the ethical principles outlined
in the Declaration of Helsinki.
Assessments
Full details of the efficacy assessments and related find-
ings have been reported elsewhere [9]. Subjects were
monitored throughout the 3-year study, with clinic visits
occurring quarterly during the first year and biannually
during the second and third years.
Safety was monitored by means of physical examina-
tions, gynecologic and breast examinations, mammogra-
phy, cervical cytology smears, clinical laboratory
determinations (including blood lipid assessments), and
recording of adverse events (AEs), which were classified
Figure 1 Subject disposition. The number of subjects who were screened, randomized and received at least 1 dose of study drug (safety popula-
tion), and completed the study is shown. aDoes not include subjects (n = 92) who completed the 3-year core study and did not enter the extension 
study. bDefined as occurrence of new vertebral fracture or ≥7% decrease in BMD of the lumbar spine or hip at any time during the study (P < 0.01 
among treatment groups, Chi-square test).Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
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using the US Food and Drug Administration's Coding
Symbols for Thesaurus of Adverse Reaction Terms
(COSTART). For subjects enrolled in the endometrial
safety substudy, TVU of the uterus and ovaries was per-
formed at baseline and at Months 12 and 24 (or upon
withdrawal from the study if more than 9 months had
elapsed since the last assessment) and endometrial biop-
sies were performed at baseline and at Month 24. Mam-
mography was performed at baseline and at Months 12,
24, and 36 (or upon withdrawal from the study if more
than 9 months had elapsed since the last assessment).
Subjects in the overall safety population who reported
abnormal uterine bleeding at any time during the study
were also evaluated by TVU and endometrial biopsy
according to a protocol-specific algorithm for the assess-
ment of uterine bleeding.
Independent blinded adjudication boards were formed
to ensure a consistent, accurate, and unbiased assessment
of the following AEs of interest: VTEs, stroke, transient
ischemic attack (TIA), and breast cancer. The adjudica-
tion boards were composed of consultant physicians spe-
cializing in the fields of internal medicine with expertise
in VTEs, cardiology, breast cancer, neurology, and neuro-
radiology. All adjudication board members reviewed each
Table 2: Overall Summary of AEs
Bazedoxifene Raloxifene Placebo
Subjects, n (%) 20 mg
(n = 1886)
40 mg
(n = 1872)
60 mg
(n = 1849) (n = 1885)
Any AE 1807 (95.8) 1792 (95.7) 1777 (96.1) 1814 (96.2)
Any serious AE 382 (20.3) 368 (19.7) 344 (18.6) 354 (18.8)
Discontinuations due 
to
AE
278 (14.7) 280 (15.0) 273 (14.8) 253 (13.4)
AEs > 10% in any
treatment group
Back pain 607 (32.2) 591 (31.6) 602 (32.6) 616 (32.7)
Arthralgia 594 (31.5) 574 (30.7) 601 (32.5) 580 (30.8)
Pain 568 (30.1) 559 (29.9) 588 (31.8) 592 (31.4)
Flu syndrome 489 (25.9) 481 (25.7) 512 (27.7) 509 (27.0)
Infection 462 (24.5) 433 (23.1) 439 (23.7) 452 (24.0)
Abdominal pain 409 (21.7) 413 (22.1) 448 (24.2) 456 (24.2)
Accidental injurya 449 (23.8) 394 (21.0) 387 (20.9) 468 (24.8)
Headache 432 (22.9) 446 (23.8) 417 (22.6) 443 (23.5)
Hypertension 396 (21.0) 379 (20.2) 375 (20.3) 394 (20.9)
Constipation 352 (18.7) 356 (19.0) 340 (18.4) 327 (17.3)
Hot flushesb 238 (12.6) 244 (13.0) 223 (12.1) 119 (6.3)
Cough increased 216 (11.5) 192 (10.3) 178 (9.6) 199 (10.6)
Leg crampsa 207 (11.0) 205 (11.0) 221 (12.0) 156 (8.3)
Asthenia 209 (11.1) 198 (10.6) 212 (11.5) 202 (10.7)
Dyspepsia 192 (10.2) 169 (9.0) 178 (9.6) 195 (10.3)
Peripheral edema 200 (10.6) 184 (9.8) 194 (10.5) 166 (8.8)
Urinary tract
infection
183 (9.7) 176 (9.4) 197 (10.7) 170 (9.0)
Dizziness 193 (10.2) 171 (9.1) 165 (8.9) 187 (9.9)
Diarrheac 165 (8.7) 209 (11.2) 211 (11.4) 182 (9.7)
AE, adverse event.
aP < 0.01; Chi-square test.
bP < 0.001; Chi-square test.
cP < 0.05; Chi-square test.Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
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case independently in a blinded manner. Thereafter, a
final decision was determined for each case based on
majority or consensus decision, according to the guid-
ance set forth in each of the adjudication board charters.
Statistical Analyses
Safety data were analyzed in all subjects who received at
least 1 dose of study medication. Differences in the inci-
dence of AEs, serious AEs, and discontinuations due to
AEs among treatment groups were evaluated using Chi-
square analysis, with a significance level set at 0.05. The
incidence of VTEs and cerebrovascular events, based on
adjudicated data, was expressed as the rate in 1,000
women-years. Hazard ratios (HRs) of treatment versus
comparator were calculated using a proportional hazard
model without adjustment for possible covariates; corre-
sponding 95% confidence intervals (CIs) and P  values
were obtained.
The median percent changes from baseline in lipid
parameters at 36 months were analyzed using an analysis
of covariance (ANCOVA) on ranked data, with treatment
as factor and baseline as covariate.
Results
Subjects
Of 26,749 women screened for the study, 7,609 women
were randomized to treatment with bazedoxifene 20 or
40 mg, raloxifene 60 mg, or placebo (Figure 1). A total of
7,492 women received ≥1 dose of study medication and
were included in the safety population. Baseline demo-
graphic and clinical characteristics were generally similar
among treatment groups (Table 1). The mean age of sub-
jects was 66.4 years. The vast majority of women (91.2%)
had experienced natural menopause, and the mean time
since last menstrual period was 19.5 years.
There were no significant differences among treatment
groups in the number of subjects who discontinued from
the study (n = 2,501 [33%]; Figure 1). The most common
reason for discontinuation was AEs. Overall, the inci-
dence of AEs, serious AEs, and discontinuations due to
AEs in the bazedoxifene treatment groups was not differ-
ent from that seen in the placebo group (Table 2). Sixty-
three subjects had deaths that resulted from AEs that
began during the study and were reported to the sponsor:
bazedoxifene 20 mg, n = 19 (1.0%); bazedoxifene 40 mg, n
= 14 (0.7%); raloxifene 60 mg, n = 19 (1.0%); and placebo,
Table 3: Incidence and Rate per 1,000 Women-Years (95% CI) of Cerebrovascular Events (Adjudicated Data)
Bazedoxifene Raloxifene Placebo
20 mg
(n = 1886)
40 mg
(n = 1872)
60 mg
(n = 1849) (n = 1885)
Total stroke
n 12 14 12 14
Rate 2.6 (1.34, 4.52) 3.1 (1.70, 5.23) 2.6 (1.36, 4.59) 3.0 (1.65, 5.06)
Hemorrhagic stroke
n 1112
Rate 0.2 (0.01, 1.20) 0.2 (0.01, 1.24) 0.2 (0.01, 1.22) 0.4 (0.05, 1.55)
Ischemic stroke
n 91 2 1 0 1 0
Rate 1.9 (0.89, 3.69) 2.7 (1.38, 4.66) 2.2 (1.05, 4.02) 2.2 (1.03, 3.96)
Stroke (unspecified)
n 2112
Rate 0.4 (0.05, 1.56) 0.2 (0.01, 1.24) 0.2 (0.01, 1.22) 0.4 (0.05, 1.55)
TIA
n 5734
Rate 1.1 (0.35, 2.52) 1.6 (0.63, 3.21) 0.7 (0.14, 1.92) 0.9 (0.23, 2.20)
Fatal stroke
n 1112
CI, confidence interval; TIA, transient ischemic attack.Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
http://www.biomedcentral.com/1471-2474/11/130
Page 6 of 11
n = 11 (0.6%). Differences between groups were not sta-
tistically significant.
The most frequently reported AEs (≥20% of subjects in
at least 1 treatment group) included back pain, arthralgia,
pain, flu syndrome, infection, abdominal pain, accidental
injury, headache, and hypertension (Table 2). The inci-
dence of leg cramps and hot flushes was higher (overall P
= 0.002 and P < 0.001, respectively) in the active treat-
ment groups compared with the placebo group. Most
reports of leg cramps and hot flushes were mild or mod-
erate in severity and did not result in study discontinua-
tion.
Cardiac disorders
Overall, the number of subjects reporting cardiac disor-
ders (n = 66 [0.9%]) was low and similar among treatment
groups. The number of subjects among the bazedoxifene
20- and 40-mg, raloxifene 60-mg, and placebo groups
reporting coronary occlusion (2 [0.1%], 0, 0, and 2 [0.1%],
respectively), myocardial infarction (8 [0.4%], 8 [0.4%], 6
[0.3%], and 8 [0.4%], respectively), and myocardial isch-
emia (7 [0.4%], 9 [0.5%], 11 [0.6%], and 9 [0.5%], respec-
tively) was not significantly different.
Cerebrovascular events
Analysis of the incidence of cerebrovascular events based
on adjudicated data showed no significant differences
among treatment groups (Table 3). The rate of total
strokes per 1,000 women-years was 2.6 with bazedoxifene
20 mg, 3.1 with bazedoxifene 40 mg, 2.6 with raloxifene
60 mg, and 3.0 with placebo (Table 3); corresponding HRs
(95% CIs) relative to placebo were 0.9 (0.40, 1.86), 1.0
(0.49, 2.17), and 0.9 (0.40, 1.88), respectively (Table 4).
There were no significant differences in the risk of stroke
(hemorrhagic, ischemic, or unspecified) or of TIA for
bazedoxifene 20 or 40 mg or raloxifene 60 mg compared
with placebo (Table 3). There were no deaths due to isch-
emic stroke in the bazedoxifene or raloxifene treatment
groups; there was 1 death due to ischemic stroke in the
placebo group. There were 4 deaths due to hemorrhagic
stroke (1 in each treatment arm).
VTEs
A total of 43 subjects (0.6%) reported VTEs based on
adjudicated data (Table 5); the overall incidence of VTEs
(deep vein thrombosis [DVT], pulmonary embolism [PE],
or retinal vein thrombosis [RVT]) was generally higher
among the active treatment groups compared with the
placebo group. The rates of any VTE per 1,000 women-
years were 2.8 with bazedoxifene 20 mg, 2.9 with baze-
doxifene 40 mg, 2.0 with raloxifene 60 mg, and 1.7 with
placebo (Table 5); corresponding HRs (95% CIs) relative
to placebo were 1.6 (0.68, 3.94), 1.7 (0.70, 4.07), and 1.1
(0.44, 2.96), respectively (Table 4). There were no signifi-
cant differences in the risk of any VTE, including DVT,
PE, and RVT, between the bazedoxifene and raloxifene
treatment groups. Reports of VTEs were highest during
t he  fi rs t  yea r o f  t h er a py wit h bazedo xif e ne  20 m g a nd
subsequently decreased over the second and third years;
no clear pattern over time was observed with bazedox-
ifene 40 mg or raloxifene 60 mg (Table 5).
The overall incidence of DVTs (n = 25 [0.3%]) and
superficial thrombophlebitis (n = 50 [0.7%]) was higher
among the active treatment groups compared with the
placebo group (Table 5). The rates of DVT per 1,000
women-years were 1.7 with bazedoxifene 20 mg, 2.0 with
Table 4: HR (95% CI) Versus Placebo for Cerebrovascular Events and VTEs (Adjudicated Data)
Bazedoxifene Raloxifene
20 mg
(n = 1886)
40 mg
(n = 1872)
60 mg
(n = 1849)
Total stroke 0.9 (0.40, 1.86) 1.0 (0.49, 2.17) 0.9 (0.40, 1.88)
Hemorrhagic stroke 0.5 (0.05, 5.53) 0.5 (0.05, 5.70) 0.5 (0.05, 5.65)
Ischemic stroke 0.9 (0.37, 2.22) 1.2 (0.54, 2.87) 1.0 (0.42, 2.44)
Stroke (unspecified) 1.0 (0.14, 7.10) 0.5 (0.05, 5.74) 0.5 (0.05, 5.54)
TIA 1.3 (0.34, 4.68) 1.8 (0.53, 6.18) 0.8 (0.17, 3.41)
Any VTE 1.6 (0.68, 3.94) 1.7 (0.70, 4.07) 1.1 (0.44, 2.96)
DVT 8.0 (1.01, 64.25) 9.4 (1.18, 73.82) 7.1 (0.88, 57.95)
PE 0.8 (0.17, 3.36) 0.8 (0.17, 3.47) 1.0 (0.25, 4.08)
RVT 0.7 (0.11, 4.00) 0.4 (0.04, 3.32) 0
Superficial thrombophlebitis 1.4 (0.55, 3.43) 2.3 (1.01, 5.33) 1.7 (0.68, 3.99)
HR, hazard ratio; CI, confidence interval; VTE, venous thromboembolic event; TIA, transient ischemic attack; DVT, deep vein thrombosis; PE, 
pulmonary embolus; RVT, retinal vein thrombosis.Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
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bazedoxifene 40 mg, 1.5 with raloxifene 60 mg, and 0.2
with placebo (Table 5); corresponding HRs (95% CI) rela-
tive to placebo were 8.0 (1.01, 64.25), 9.4 (1.18, 73.82), and
7.1 (0.88, 57.95), respectively (Table 4). There were no dif-
ferences in the risk of PE or RVT with bazedoxifene 20 or
40 mg or raloxifene 60 mg compared with placebo.
Breast and reproductive safety
The rates of breast- and reproductive system-related AEs
are shown in Table 6. The incidence of breast carcinoma
and breast cysts was not significantly different among
treatment groups, although the number of cases was
lower with bazedoxifene 20 and 40 mg compared with
placebo or raloxifene 60 mg. Reports of breast pain were
evenly distributed among treatment groups. The inci-
dence of fibrocystic breast disease was lower in the baze-
doxifene 20- and 40-mg groups compared with the
raloxifene 60-mg or placebo group, and was significantly
lower in the bazedoxifene 20-mg group compared with
the raloxifene 60-mg group (P = 0.050) and in the baze-
doxifene 40-mg group compared with the raloxifene 60-
mg group (P = 0.011).
TVU data were available for a total of 753 subjects;
after 2 years, there were no differences in the change in
mean endometrial thickness (± standard error) from
baseline with bazedoxifene 20 mg (-0.07 ± 0.11 mm),
bazedoxifene 40 mg (0.10 ± 0.11 mm), raloxifene 60 mg
(0.16 ± 0.12 mm), or placebo (-0.08 ± 0.11 mm). Endome-
trial hyperplasia was reported by 1 subject in each treat-
ment group, and endometrial carcinoma was reported by
0, 2, 2, and 3 subjects in the bazedoxifene 20- and 40-mg,
raloxifene 60-mg, and placebo groups, respectively. The
incidence of uterine or vaginal bleeding was low and sim-
ilar among treatment groups.
Lipid parameters
The median percent changes from baseline in total and
LDL cholesterol were significantly reduced in the baze-
doxifene and raloxifene treatment groups compared with
the placebo group after 36 months (P < 0.001; Table 7).
Table 5: Incidence and Rate per 1,000 Women-Years (95% CI) of VTEs (Adjudicated Data)
Bazedoxifene Raloxifene Placebo
20 mg
(n = 1886)
40 mg
(n = 1872)
60 mg
(n = 1849)
(n = 1885)
Any VTE
n 13 13 9 8
Year 1 8423
Year 2 4642
Year 3 1333
Rate 2.8 (1.49, 4.79) 2.9 (1.54, 4.94) 2.0 (0.90, 3.74) 1.7 (0.74, 3.39)
Year 1 4.6 (2.00, 9.14) 2.4 (0.65, 6.09) 1.2 (0.14, 4.29) 1.7 (0.36, 5.05)
Year 2 2.7 (0.73, 6.83) 4.2 (1.53, 9.05) 2.7 (0.74, 6.93) 1.3 (0.16, 4.82)
Year 3 0.7 (0.02, 3.94) 2.2 (0.45, 6.38) 2.1 (0.44, 6.22) 2.1 (0.44, 6.20)
DVT
n 8971
Rate 1.7 (0.74, 3.40) 2.0 (0.92, 3.80) 1.5 (0.62, 3.15) 0.2 (0.01, 1.20)
PE
n 3344
Rate 0.7 (0.13, 1.89) 0.7 (0.14, 1.95) 0.9 (0.24, 2.24) 0.9 (0.23, 2.20)
RVT
n 2103
Rate 0.4 (0.05, 1.56) 0.2 (0.01, 1.24) 0 (0.00, 0.66) 0.7 (0.13, 1.89)
Superficial thrombophlebitis
n 11 18 13 8
Rate 2.4 (1.19, 4.25) 4.0 (2.38, 6.34) 2.9 (1.52, 4.87) 1.7 (0.74, 3.40)
CI, confidence interval; VTE, venous thromboembolic event; DVT, deep vein thrombosis; PE, pulmonary embolism; RVT, retinal vein 
thrombosis.Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
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The reduction in total and LDL cholesterol was signifi-
cantly greater (P < 0.01) in the raloxifene treatment group
than in the bazedoxifene 20- or 40-mg treatment groups.
The increase in levels of HDL cholesterol was signifi-
cantly greater in the active treatment groups compared
with the placebo group after 36 months (P < 0.001). Trig-
lyceride levels were significantly increased from baseline
in all treatment groups (P < 0.001); however, there were
no differences in the median percent change from base-
line among treatment groups.
Discussion
SERMs represent a growing class of compounds that are
under development for the prevention and/or treatment
of postmenopausal osteoporosis. Because certain "class
effects" are associated with SERMs, including increased
incidence of hot flushes, leg cramps, and VTEs [11-14], as
well as the potential for endometrial effects/stimulation,
a careful evaluation of the safety and tolerability profile of
each SERM is of considerable importance.
Findings from this large, prospective phase 3 study
showed that bazedoxifene was associated with a favorable
safety and tolerability profile in postmenopausal women
with osteoporosis over 3 years of therapy. Overall, the
incidence of AEs, serious AEs, and discontinuations due
to AEs with bazedoxifene was similar to that seen with
placebo. Although the current study showed an increased
incidence of hot flushes and leg cramps in the active
treatment groups, most of these events were mild or
moderate in severity and did not lead to study discontinu-
ation.
Ov e r a l l ,  VT Es  w e r e  m o r e  fr eq u e n t l y  r e po rt ed  i n  t h e
bazedoxifene groups compared with the placebo group.
This was primarily the result of a significantly increased
incidence of DVTs, while the incidence of PE or RVT was
not different among all treatment groups. The relative
risk of VTEs with bazedoxifene (HR, 1.6-1.7) was consis-
tent with that previously reported with raloxifene (HR,
2.1-3.1) [13,14] and lasofoxifene (HR, 2.2-2.6) [15]. In
addition, the rate of VTEs with placebo (1.7 per 1,000
women-years) in this study was similar to that seen in
earlier studies of raloxifene (1.7 per 1,000 women-years)
[14] and lasofoxifene (1.2 per 1,000 women-years) [15].
Collectively, these findings provide strong external vali-
dation of the risk estimates observed with bazedoxifene
in the present study.
Table 6: Incidence of Breast- and Reproductive System-related AEs
Bazedoxifene Raloxifene Placebo
Subjects, n (%) 20 mg
(n = 1886)
40 mg
(n = 1872)
60 mg
(n = 1849)
(n = 1885)
Breast carcinoma 6 (0.3) 4 (0.2) 7 (0.4) 8 (0.4)
Breast cyst 8 (0.4) 10 (0.5) 17 (0.9) 11 (0.6)
Fibrocystic breast 
diseasea
6 (0.3) 4 (0.2) 15 (0.8) 9 (0.5)
Breast neoplasmb 12 (0.6) 14 (0.7) 11 (0.6) 22 (1.2)
Breast pain 53 (2.8) 45 (2.4) 56 (3.0) 48 (2.5)
Endometrial 
carcinoma
0 2 (0.1) 2 (0.1) 3 (0.2)
Endometrial 
hyperplasia
1 (0.1) 1 (0.1) 1 (0.1) 1 (0.1)
Endometrial 
neoplasiac
9 (0.5) 12 (0.6) 12 (0.6) 10 (0.5)
Ovarian carcinoma 3 (0.2) 0 2 (0.1) 0
Ovarian cyst 16 (0.8) 8 (0.4) 13 (0.7) 14 (0.7)
Uterine hemorrhage 3 (0.2) 5 (0.3) 4 (0.2) 3 (0.2)
Vaginal hemorrhage 16 (0.8) 18 (1.0) 22 (1.2) 23 (1.2)
AE, adverse event.
aP < 0.05; Chi-square test.
bEvents reported as breast neoplasm included breast mass, breast lump, solid formation, lipoma, fibroadenoma, tumor, nodule, 
microcalcification, intracanalar papilloma, and cyst.
cEvents reported as endometrial neoplasia included endometrial polyps, uterine polyps, thickening of endometrium due to polyps, 
hyperplastic endometrial polyps, accentuated cystocele and polyps, and endometrial polyps with cystic atrophy (benign).Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
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The rate of VTEs was highest during the first year of
therapy with bazedoxifene 20 mg and subsequently
decreased over the second and third years; such a pattern
was not seen with bazedoxifene 40 mg or raloxifene 60
mg, although a decrease in VTE risk over time has previ-
ously been reported with raloxifene (HR, 6.0, 6.6, 0.9 at
Years 1, 2, and 3, respectively) [14]. Overall, the absolute
risk of VTEs was low among all treatment groups in the
current study, with the attributable risk for bazedoxifene
estimated at 1 case per 1,000 women-years (ie, 100
women over 10 years of treatment).
Raloxifene has been associated with a 2- to 3-fold
increase in VTE risk over 3 years (1.4-fold increase over 5
years) in previous studies [13,14,16], which was higher
than that seen in this study. The reason for this discrep-
ancy is unclear and may be attributed to the small num-
ber of VTEs reported in the current study . The risk of
DVTs, however, was similarly increased with raloxifene
relative to placebo in the current study and in previous
studies of raloxifene [13,14,16].
The incidence of cardiac disorders and cerebrovascular
events in the active treatment groups was not different
from that seen in the placebo group. Raloxifene has previ-
ously been associated with a small but significant
increase in the risk of fatal stroke compared with placebo
(1.49; 95% CI, 1.00-2.24; P = 0.05), although there was no
difference in the overall incidence of stroke [16]. In the
current study, there were no deaths due to ischemic
stroke with bazedoxifene or raloxifene; there was 1 case
of death due to hemorrhagic stroke in each treatment
arm.
Endometrial safety is an important consideration for
investigational SERMs, as the clinical development of
several SERMs for postmenopausal osteoporosis (eg,
idoxifene, levormeloxifene) in recent years was discontin-
ued, in part, because of unfavorable uterine effects
[17,18]. In this study, bazedoxifene was associated with
an excellent endometrial safety profile and a neutral
effect on the breast over 3 years of therapy. There was no
difference in the rates of endometrial hyperplasia or car-
cinoma with bazedoxifene compared with placebo, or in
the change in endometrial thickness. The incidence of
breast- and reproductive system-related AEs were small
and similar among groups. There was a lower incidence
of fibrocystic breast disease in the bazedoxifene treat-
m e n t  g r o u p s  c o m p a r e d  w i t h  t h e  r a l o x i f e n e  o r  p l a c e b o
group. Raloxifene was not associated with a reduction in
the incidence of breast cancer in this study, which is in
contrast to findings from previous studies [16,19,20] and
may be attributable to the relatively smaller number of
Table 7: Median Percent Changes From Baseline in Selected Lipid Parameters at Month 36a
Bazedoxifene Raloxifene Placebo
Parameter 20 mg 40 mg 60 mg
Total cholesterol
No. of pairs 1220 1201 1225 1248
Median percent change -3.8b,c,d -3.5b,c,d -5.0b,c 0.3
LDL cholesterol
No. of pairs 1220 1201 1223 1247
Median percent change -5.4b,c,d -6.6b,c,d -8.5b,c 1.6b
HDL cholesterol
No. of pairs 1216 1196 1219 1246
Median percent change 5.1b,c 5.9b,c 5.0b,c 2.5b
LDL/HDL cholesterol
No. of pairs 1213 1191 1215 1244
Median percent change -10.5b,c,d -12.6b,c -12.4b,c -0.6
Triglycerides
No. of pairs 1220 1201 1225 1248
Median percent change 8.5b 13.6b 12.2b 12.1b
LDL, low-density lipoprotein; HDL, high-density lipoprotein.
aIncludes subjects in the intent-to-treat population (n = 6,847) with an assessment at baseline and at Month 36.
bP < 0.001 vs baseline; t test.
cP < 0.001 vs placebo; t test.
dP < 0.01 vs raloxifene 60 mg; t test.Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130
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subjects evaluated and the lower baseline risk for breast
cancer (mean Gail Index 5-year risk score of 1.59). In this
study, the overall incidence of breast cancer in the pla-
cebo groups was lower than that observed in other clini-
cal trials [8,14,19].
Bazedoxifene was associated with favorable effects on
the lipid profile. Significant reductions in the levels of
total and LDL cholesterol and significant increases in lev-
els of HDL cholesterol were observed with bazedoxifene
compared with placebo. Triglyceride levels were similar
among all treatment groups. The clinical significance of
these results is unknown. Overall, findings are consistent
with those seen in the 2-year phase 3 study evaluating the
efficacy and safety of bazedoxifene in postmenopausal
women at risk for osteoporosis [7].
Conclusions
Overall, bazedoxifene was associated with a favorable
safety and tolerability profile over 3 years of therapy, with
no evidence of endometrial or breast stimulation. Baze-
doxifene was associated with a small increase in the risk
of VTEs, consistent with that seen with other SERMs,
including raloxifene and lasofoxifene; however, the abso-
lute risk of VTEs was low and did not increase over time.
Combined with its demonstrated efficacy in preventing
new vertebral fractures in postmenopausal women with
osteoporosis, as well as in preventing nonvertebral frac-
tures in higher-risk women [9], bazedoxifene appears to
have a favorable risk-benefit profile in the treatment of
postmenopausal women with osteoporosis.
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